Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty

Purpose This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit. Methods We conducted a retrospective analysis of 200...

Full description

Saved in:
Bibliographic Details
Main Authors: Jung Hwangbo, Eungu Kang, Hyo-Kyoung Nam, Young-Jun Rhie, Kee-Hyoung Lee
Format: Article
Language:English
Published: Korean Society of Pediatric Endocrinology 2025-02-01
Series:Annals of Pediatric Endocrinology & Metabolism
Subjects:
Online Access:http://e-apem.org/upload/pdf/apem-2448038-019.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850176050052464640
author Jung Hwangbo
Eungu Kang
Hyo-Kyoung Nam
Young-Jun Rhie
Kee-Hyoung Lee
author_facet Jung Hwangbo
Eungu Kang
Hyo-Kyoung Nam
Young-Jun Rhie
Kee-Hyoung Lee
author_sort Jung Hwangbo
collection DOAJ
description Purpose This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit. Methods We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit. Results The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8–9 years). Conclusions GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.
format Article
id doaj-art-b8f37f35a5e7439a814bccbbee0dccf0
institution OA Journals
issn 2287-1012
2287-1292
language English
publishDate 2025-02-01
publisher Korean Society of Pediatric Endocrinology
record_format Article
series Annals of Pediatric Endocrinology & Metabolism
spelling doaj-art-b8f37f35a5e7439a814bccbbee0dccf02025-08-20T02:19:19ZengKorean Society of Pediatric EndocrinologyAnnals of Pediatric Endocrinology & Metabolism2287-10122287-12922025-02-01301313710.6065/apem.2448038.0191080Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious pubertyJung Hwangbo0Eungu Kang1Hyo-Kyoung Nam2Young-Jun RhieKee-Hyoung Lee3 Department of Pediatrics, Korea University College of Medicine, Seoul, Korea Department of Pediatrics, Korea University College of Medicine, Seoul, Korea Department of Pediatrics, Korea University College of Medicine, Seoul, Korea Department of Pediatrics, Korea University College of Medicine, Seoul, KoreaPurpose This study aimed to examine the effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on final height outcomes in girls with idiopathic central precocious puberty (CPP) from the start of treatment to their postmenarche visit. Methods We conducted a retrospective analysis of 200 girls with idiopathic CPP who received GnRHa therapy, focusing on auxological and clinical outcomes at treatment initiation, treatment completion, and the last, postmenarche visit. Results The mean chronological age (CA) at GnRHa treatment initiation was 8.24±0.73 years. The mean duration of GnRHa treatment was 3.12±0.81 years. The average age at menarche was 12.73±0.56 years, occurring a mean of 17.15±5.52 months after completing GnRHa therapy. The predicted adult height (PAH) standard deviation score (SDS) after menarche (0.48±0.99) was significantly greater than before treatment (-1.33±1.46) (P<0.001). Factors including greater bone age advancement (P<0.001), lower height SDS for CA at treatment initiation (P<0.001), and higher midparental height SDS (P=0.001) were positively associated with an increase in PAH SDS at the last visit. However, near-final height and the increase in PAH SDS at the last visit were not significantly different between patients who received early treatment (<8 years) and those who received later treatment (8–9 years). Conclusions GnRHa treatment improved the final height outcomes in all girls with CPP, including those treated between 8 and 9 years of age.http://e-apem.org/upload/pdf/apem-2448038-019.pdfcentral precocious pubertygonadotropin-releasing hormone agonistpredicted adult heighttreatment outcomemenarche
spellingShingle Jung Hwangbo
Eungu Kang
Hyo-Kyoung Nam
Young-Jun Rhie
Kee-Hyoung Lee
Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
Annals of Pediatric Endocrinology & Metabolism
central precocious puberty
gonadotropin-releasing hormone agonist
predicted adult height
treatment outcome
menarche
title Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
title_full Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
title_fullStr Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
title_full_unstemmed Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
title_short Long-term outcomes of gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
title_sort long term outcomes of gonadotropin releasing hormone agonist treatment in girls with central precocious puberty
topic central precocious puberty
gonadotropin-releasing hormone agonist
predicted adult height
treatment outcome
menarche
url http://e-apem.org/upload/pdf/apem-2448038-019.pdf
work_keys_str_mv AT junghwangbo longtermoutcomesofgonadotropinreleasinghormoneagonisttreatmentingirlswithcentralprecociouspuberty
AT eungukang longtermoutcomesofgonadotropinreleasinghormoneagonisttreatmentingirlswithcentralprecociouspuberty
AT hyokyoungnam longtermoutcomesofgonadotropinreleasinghormoneagonisttreatmentingirlswithcentralprecociouspuberty
AT youngjunrhie longtermoutcomesofgonadotropinreleasinghormoneagonisttreatmentingirlswithcentralprecociouspuberty
AT keehyounglee longtermoutcomesofgonadotropinreleasinghormoneagonisttreatmentingirlswithcentralprecociouspuberty